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Abstract
Background: Histone deacetylase inhibitors (HDACis) are promising anticancer drugs; however, the molecular mechanisms
leading to HDACi-induced cell death have not been well understood and no clear mechanism of resistance has been
elucidated to explain limited efficacy of HDACis in clinical trials.
Methods and Findings: Here, we show that protein levels of checkpoint kinase 1 (Chk1), which has a major role in G2 cell
cycle checkpoint regulation, was markedly reduced at the protein and transcriptional levels in lung cancer cells treated with
pan-and selective HDACis LBH589, scriptaid, valproic acid, apicidin, and MS-275. In HDACi treated cells Chk1 function was
impaired as determined by decreased inhibitory phosphorylation of cdc25c and its downstream target cdc2 and increased
expression of cdc25A and phosphorylated histone H3, a marker of mitotic entry. In time course experiments, Chk1
downregulation occurred after HDACi treatment, preceding apoptosis. Ectopic expression of Chk1 overcame HDACi-
induced cell death, and pretreating cells with the cdc2 inhibitor purvalanol A blocked entry into mitosis and prevented cell
death by HDACis. Finally, pharmacological inhibition of Chk1 showed strong synergistic effect with LBH589 in lung cancer
cells.
Conclusions: These results define a pathway through which Chk1 inhibition can mediate HDACi-induced mitotic entry and
cell death and suggest that Chk1 could be an early pharmacodynamic marker to assess HDACi efficacy in clinical samples.
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Introduction
Histone deacetylase inhibitors (HDACis) represent a promising new
class of compounds for the treatment of cancer [1]. Some HDACis
show broad activity against multiple HDAC classes (scriptaid,
LBH589), whereas others are class-or isotype selective (MS-275) [1,2].
The precise mechanisms by which HDACis exert their cytotoxic
effects are unknown; however, the antitumor effects of these drugs are
thought to result from hyperacetylation of histones, demethylation of
genomic DNA, and activation of genes that inhibit proliferation and
induce apoptosis [1]. In addition to their epigenetic effects, HDACis
have also been shown to have significant post-translational effects on
non-histone proteins, including transcription factors p53, heat-shock
protein 90 (HSP90), and a-tubulin [3]. Besides direct anti-tumorigenic
effects, suppression of angiogenesis by HDACis might also have an
impact on tumor growth inhibition [4].
An essential regulatory step for the G2/M cell cycle transition in
eukaryotes is activation of the cdc2-cyclin B complex [5]. The
proper regulation of cdc2 requires an activating phosphorylation
on threonine-161 and inhibitory phosphorylations on threonine-
14 and tyrosine-15 (Tyr15) [6]. The inhibitory phosphorylation on
Tyr15 maintains the cdc2-cyclin B complex in an inactive state if
there is incompletely replicated DNA or damaged DNA in the cell
[7,8]. Cdc2 activation through removal of its inhibitory phos-
phorylation by cdc25 phosphatases allows cells to enter the mitotic
phase of the cell cycle [9]. Chk1 is a critical component of DNA
replication, intra-S phase, G2/M phase, and mitotic spindle-
assembly checkpoints [10]. In response to a variety of genotoxic
stressors, Chk1 becomes activated by upstream kinases such as
ATM and ATR, leading to increased proteosomal degradation of
the phosphatase cdc25A and inhibition of cdc25C through serine-
216 (Ser216) phosphorylation, collectively causing inactivation of
cdc2 and consequently G2/M arrest [10–14].
Furthermore, combining HDACis with regulators of G2
checkpoint could improve efficacy and aid in overcoming
resistance. In fact, direct pharmacologic inhibition or siRNA
knockdown of Chk1 has been shown to cause checkpoint
abrogation, cytokinetic regression, and multinucleation, as well
as chromosome missegregation and chromosomal instability [15].
Therefore, Chk1 inhibitors, which effectively abrogate the S and
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or in combination with cytotoxic agents [16–18] and could be
effectively combined with HDACi to enhance cytotoxic effects.
Here, we demonstrate that HDACi treatment downregulates
Chk1 protein expression, which in turn leads to unscheduled cdc2
activation, mitotic entry, and cell death in human lung cancer
cells. The results of this study demonstrate that Chk1 downreg-
ulation and abrogation of G2 checkpoint are important regulatory
steps in sensitivity and resistance to the cytotoxic effect of HDACi
treatment in non-small cell lung cancer (NSCLC) cells. Our data
suggest that Chk1 might be an early pharmacodynamic marker to
predict and assess the efficacy of HDACis and Chk1 inhibitors
may enhance cytotoxic effects of HDACis in clinical studies.
Results
Treatment of NSCLC cells with HDACis causes G2/M cell
cycle arrest and cell death
Previous studies have demonstrated that a pan-HDACi
LBH589 (IC50 ranging between approximately 9 and 54 nmol/
L) causes growth arrest and cell death in NSCLC cells [19]. To
analyze the molecular mechanisms by which HDACis regulate cell
cycle progression and cell death, asynchronously growing A549
(EGFR wild type, K-Ras mutant, and p53 wild type) and PC9
(EGFR mutant, K-ras wild type, and p53 mutant) [20–22] cells
were treated with LBH589 (40 nM) for 24 hours and collected for
flow cytometric analysis. Figure 1 shows that in PC9 and A549
cells LBH589 treatment produced a noticeable increase in the cells
in the G2/M phase suggestive of a G2/M blockade and a
significant reduction in S-phase cells. These results are in
agreement with the previous reports that HDACis lead to G2/M
arrest and apoptotic cell death in NSCLC cells [19].
As illustrated in Figure 2A, microscopic examination of cells
treated with LBH589 produced a range of different nuclear
morphologies, from binucleation to multinucleation. Taken
together, these data show that LBH589 treatment causes cell
death associated with abnormal mitosis and failed cytokinesis,
which is suggestive of mitotic catastrophe, a type of cell death that
occurs during mitosis and has previously been described in cells
treated with the HDACi trichostatin A [23].
Figure 1. Effect of LBH589 on cell cycle distribution of A549 and PC9 cells. A, The asynchronously growing cells were incubated in medium
with 5% FCS for 24 hours in the absence (control, C) or presence (L) of LBH589. The percentage of cells in different phases of the cell cycle was
determined by flow cytometric analysis. B, Histogram representation of cell cycle data determined by flow cytometric analysis.
doi:10.1371/journal.pone.0014335.g001
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on their differences in DNA content by flow cytometric analysis, we
tested whether cells arrested in G2/M after HDACi treatment enter
mitotic phase. For this purpose, we first performed immunofluores-
cence staining using the antibody against cleaved poly(ADP-ribose)
polymerase (cPARP) and showed that LBH589 treatment causes
apoptotic cell death in 78% of binucleated mitotic cells (Figure 2B).
Next, in Western blot analysis we tested whether HDAC inhibition
enhanceshistone H3 phosphorylation at serine-10,which takesplace at
the onset of mitosis. Figure 2C illustrates that LBH589 treatment
caused histone H3 phosphorylation accompanied by increased histone
acetylation and PARP cleavage, indicating that HDACi treatment
causes NSCLC cells to enter mitosis and undergo cell death. To
determine whether cell growth and viability changes observed after
LBH589 treatment are a generalized effect of HDAC inhibition, we
also used another pan-HDACi, scriptaid (1 mM), which produced
biochemical changes indistinguishable from those presented above
using LBH589 (Figure 3).
HDAC inhibition results in activation of cdc25 and cdc2
proteins that are required for mitotic entry
Activation of the cdc2 protein kinase by the cdc25 protein
phosphatases is a pivotal regulatory step for the G2/M transition in
eukaryotes [9]. The dephosphorylation of cdc25C on Ser216
increases its activity during M-phase transition, leading to
activation of the cdc2 kinase [10]. To investigate whether
HDACi-induced mitotic entry and cell death are mediated by
activation of the cdc25/cdc2 pathway, PC9, A549, H1299, H292,
H358, H441 and HCC827 cells were treated with or without
LBH589, and Western blot analysis was performed. Figure 3A
shows HDACi treatment resulted in increased levels of PARP
cleavage, a decrease in the inhibitory phosphorylation on cdc2 and
45–94% decrease (based on quantitative Western blot analysis) in
total Chk1 across the 7 different NSCLC cell lines, with A549s
showing the most significant decrease in Chk1 protein. These
changes are all associated with an increase in histone acetylation.
Further investigation of A549 and PC9 cells treated with pan
HDACis (Figure 3B), LBH589 and scriptaid, showed activation of
cdc25C and cdc2, as assessed by a decrease in their inhibitory
phosphorylation on Ser216 and Tyr15, respectively, which were
accompanied by increased histone H4 acetylation. No decrease
was observed in the expression levels of total cdc25C and cdc2
proteins (Figure 3B). These results indicate that HDACi-induced
mitotic entry is mediated by increased cdc25/cdc2 activity.
Furthermore, HDACi treatment also increased the expression
level of cdc25A, which is targeted by Chk1 for rapid degradation
Figure 2. LBH589 treatment leads to mitotic abnormalities and cytokinesis failures. A549 cells were treated with vehicle (control) or
40 nM LBH589 for 24 hours. A, arrows show bi- or multinucleated cells with impaired cytokinesis in LBH589-treated NSCLC cells. B, cells were fixed
and stained with DAPI or cleaved poly (ADP-ribose) polymerase (cPARP) antibody (6100 or 6400 magnification). C, Western blot analysis
demonstrating that HDAC inhibition by LBH589 causes histone H3 phosphorylation (H3-P10), histone H4 acetylation (Acety-H4), and PARP cleavage
(cPARP) in A549 cells treated with LBH589 for 24 hours. b-actin was used as loading control.
doi:10.1371/journal.pone.0014335.g002
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biologic function of Chk1 was inhibited.
Besides phosphorylation at the Tyr15 position, another major
mechanism regulating cdc2 activity and progression into mitotic
phase of the cell cycle is its complex formation with cyclin B, a
required cofactor for the cdc2 kinase activity. Thus, we next
determined whether HDACi treatment affects cyclin B expression
levels. As shown in Figure 3B, NSCLC cells treated with LBH589
or scriptaid displayed higher overall levels of cyclin B1 expression.
Taken together with the decreased Tyr15 phosphorylation of
cdc2, this finding implies a high cdc2-cyclin B activity in HDACi-
treated cells, providing further support that cells treated with
HDACis are capable to enter mitosis.
Inhibition of HDAC activity correlates with decreased
Chk1 expression in NSCLC cells
The order and fidelity of the cell cycle are linked to the integrity
of the Chk1 and cdc25 phosphatase pathways. Maintenance of the
Chk1/cdc25 pathway is essential for cells to progress normally
through an unperturbed cell division cycle and for cells to arrest in
response to checkpoint activation [10].
To determine the role of Chk1 in HDACi-induced activation of
cdc25C and cdc2, we analyzed changes in the levels of Chk1
protein in cells treated with HDACis. Immunoblot analysis
revealed that treatment with LBH589 or scriptaid causes a
significant decrease in the expression of Chk1 protein (Figure 3C).
This inhibition appears to be specific since no change was
Figure 3. HDACi treatment specifically inhibits CHK1 expression and upregulates its downstream signaling proteins CDC25A,
CDC25C, and CDC2, involved in G2 cell cycle checkpoint control. A, A549, PC9, H1299, H292, H358, H441 and HCC827 cells were cultured in
the presence of vehicle (C), or LBH589 (LBH) 40 nM for 24 hours and expression levels of cPARP, phosphorylation of CDC2 (pCDC2
Y15), CHK1, and
acetylated histone H4 (acetyl-H4) were determined by Western blot and quantitated using AlphaEase software. b-actin was used as loading control. B,
PC9 and A549 cells were cultured in the presence of vehicle (C), or LBH589 (LBH) 40 nM, or scriptaid (S) 1 mM for 24 hours and expression levels of
cPARP, tyrosine-15 phosphorylation of CDC2 (pCDC2
Y15), serine-216 phosphorylation of CDC25C (pCDC25c
S216), CDC25A (T-CDC25A), CDC25C (T-
CDC25C) and CDC2 (T-CDC2), acetylated histone H4 (acetyl-H4), and cyclin B1 were determined by Western blot analysis. b-actin was used as loading
control. C, drug-mediated changes in the expression of CHK1, CHK2, AKT, and c-RAF were determined by Western blot analysis. b-actin was used as
loading control. D, PC9 or A549 cells were treated with or without 40 nM LBH589 and analyzed for annexin positive cells using the BD Annexin V-
FITC/7-AAD Flow Cytometry kit. E, A549 cells were treated with MS-275 (MS), (500 nM), valproic acid (VA) (1 Mm), or apicidin (Api) (400 nM) for 24 h.
Expression levels of cPARP, CHK1, pCDC2
Y15, and b-actin were determined by Western blot analysis. All experiments were repeated at least three
times.
doi:10.1371/journal.pone.0014335.g003
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DNA-damage checkpoint signaling pathway [10,11].
HDACis, including LBH589, have been reported to function-
ally inactivate HSP90 through protein acetylation, leading to
depletion of the client proteins such as AKT and c-RAF [22].
Interestingly, Chk1 protein has also been reported to be an HSP90
client [24,25], suggesting that inactivation of HSP90 by HDACis
might be responsible for degradation of Chk1 observed in our
experiments. To test this possibility, we analyzed whether Chk1
downregulation coincides with decreased expression of AKT and
c-RAF in extracts prepared from cells treated with LBH589 or
scriptaid. As illustrated in Figure 3C, no changes were observed in
the expression levels of AKT or c-RAF proteins under the
conditions where LBH589 and scriptaid caused Chk1 downreg-
ulation.
To further demonstrate the cytotoxic effects of HDACi
treatment on NSCLC cells we measured apoptotic cell death
using Annexin V detection. As shown in Figure 3D, PC9 and
A549 cells showed a measured increase in the amount of annexin
positive cells indicating that treatment with HDACi results in
significant increase in cells undergoing apoptosis.
To determine whether selective HDACis also cause Chk1
inhibition, A549 and PC9 cells were treated with MS-275 that
selectively inhibits HDAC1, and to lesser extent HDAC3. As
illustrated in Figure 3E, MS-275 (0.5 mM) produced changes in the
expression of Chk1, phosphorylated cdc2 (Tyr15), and cPARP
similar to results observed with LBH589 and scriptaid. Two other
class I HDACis valproic acid (1 mM) and apicidin (400 nM) also
produced identical results (Figure 3E). These data demonstrate
that HDACi-mediated Chk1 downregulation is not drug depen-
dent and class I HDACs are likely mediators of the HDACi effect
on Chk1 downregulation in NSCLC cells.
Chk1 abrogation precedes initiation of apoptosis by
LBH589
Chk1 has been reported to be subject to caspase-mediated
degradation in cells undergoing apoptotic cell death [26].
Consequently, we analyzed in time course experiments whether
downregulation of Chk1 protein observed in HDACi-treated cells is
the cause or the consequence of apoptotic cell death. As shown in
Figure 4A, treatment of A549 cells with LBH589 led to a 70%
decrease in Chk1 protein within 1 hour of treatment, based on
quantitation of western blots, which was accompanied by decreased
phospho-cdc25C (Ser216) and phospho-cdc2 (Tyr15) levels consis-
tent with functional inactivation of Chk1 activity. Of importance,
these changes occurred before detectable caspase activation, as
evidenced by PARP cleavage that was first observed at 12 hours of
treatment. A similar time course profile was observed in PC9 cells
treated with LBH589 or scriptaid (data not shown).
Collectively, these results support a model where inhibition of
Chk1 expression by HDACis leads to cell death through
unscheduled activation of the mitosis-promoting kinase cdc2 in
NSCLC cells.
HDACi treatment leads to the transcriptional
downregulation of Chk1
To determine whether HDACi treatment regulates Chk1
expression at the transcriptional level in NSCLC cells, we
performed real-time PCR. As illustrated in Figure 4B, quantitative
RNA analysis revealed more than a 50% reduction in Chk1
mRNA levels in A549 cells 24 hours after LBH589 (40 nM)
treatment. This finding demonstrates that HDACi treatment leads
to transcriptional repression of Chk1 in NSCLC cells.
Ectopic expression of Chk1 overcomes LBH589-induced
apoptosis
To determine the importance of Chk1 downregulation in
HDACi-induced apoptotic cell death, we aimed to determine
whether ectopic expression of Chk1 can overcome cell death
triggered by LBH589. Therefore, A549 cells were transiently
transfected with a Chk1 plasmid encoding a GFP-tagged Chk1
fusion protein. As shown in Figure 4C, transient expression of
ectopic Chk1 protein suppressed LBH589-induced apoptosis, as
detected by PARP protein cleavage. Additionally, in cells
expressing ectopic Chk1, LBH589 treatment failed to activate
cdc2, as assessed by Tyr15 dephosphorylation (Figure 4C), while
no changes were observed in HDACi-induced histone acetylation.
Similar data were obtained with a Flag-tagged Chk1 expression
plasmid in NSCLC cells (Figure 4C). These results indicate that
Chk1 downregulation plays an essential role in HDACi-mediated
cell death.
Chk1 downregulation correlates with apoptotic cell
death in primary NSCLC cells treated with LBH589 ex vivo
To verify the downregulation of Chk1 in clinically relevant
tumor samples, tumor cells collected from NSCLC patient tumors
were treated ex vivo with LBH589. Total proteins were extracted,
and drug-mediated changes in the expression of Chk1, histone
acetylation, and PARP cleavage were analyzed by Western blot.
As illustrated in Figure 4D, ex vivo treatment of cells with LBH589
(40 nM) caused increased histone H4 acetylation in all tumor
samples, whereas, LBH589 treatment increased PARP cleavage in
only 2 of 5 samples, which closely correlates with Chk1
downregulation. These results support the findings presented
above with NSCLC cell lines and suggest that decreased Chk1 and
phospho-cdc2 (Tyr15) levels may be sensitive pharmacodynamic
markers for HDACi efficacy in patient tumor samples to predict
and assess patient response to HDACi treatment in clinical studies.
HDACi-mediated cell death requires mitotic entry
The data presented above support a model where failure of
Chk1-mediated checkpoint activation plays an essential role in
HDACi-mediated cell death. Thus, we hypothesize that blockade
of mitotic entry would diminish the sensitivity of cancer cells to the
cytotoxic effects of HDACi treatment. To test this hypothesis,
A549 cells were pretreated with a potent cdc2 inhibitor,
purvalanol A [27], to block entry into mitosis. Flow cytometric
analysis illustrates that 40 nM LBH589 for 24 hours caused a
significant increase of cells in G2/M and an approximately 20-fold
increase of the sub-G1 peak (hypodiploid cells) after 24 hours of
treatment, consistent with increased cell death. The increase in the
sub-G1 population after LBH589 treatment, however, was
significantly reduced by pretreatment of cells with purvalanol A
(Figure 5), indicating that mitotic blockade causes resistance to the
cytotoxic effects of LBH589. To confirm this observation, we
performed Western blot analysis with extracts prepared from A549
cells exposed to LBH589 with or without purvalanol A
pretreatment. Figure 5 illustrates that purvalanol A pretreatment
inhibited LBH589-induced apoptotic cell death, as measured by
cPARP, providing further support that HDACi-induced cell death
largely requires entry into mitosis.
HDAC and Chk1 inhibitors show a synergistic effect in
NSCLC cells
Our results showed that HDACi treatment targets Chk1 to
induce inappropriate mitotic entry and thereby exerts its cytotoxic
effects on tumor cells. The diminished sensitivity of cells to HDACi
HDAC Inhibitors Diminish Chk1
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14335treatment observed in A549 cells ectopically expressing Chk1
(Figure 4C) suggests that activation of Chk1 and its downstream
signaling pathway, which control the G2 check point, may cause
resistance to HDACi therapy. Thus, it is plausible that Chk1
inhibitors may potentiate cytotoxic effects of HDACis in tumor
cells that are resistant to HDACis. To test this possibility, A549
cells were treated with LBH589 and a Chk1 inhibitor (UCN-01)
for 24 hours. Figure 6A shows that, at low concentrations, neither
LBH589 (4 nM) nor UCN-01 (250 nM) alone can cause PARP
cleavage in A549 cells, whereas the combination of these two
drugs drastically increased PARP protein cleavage, suggesting a
potential synergy. To corroborate the synergistic interaction
between HDAC and Chk1 inhibitors, we next performed median
dose effect analysis. For this purpose, A549 cells were exposed to
increasing concentrations of LBH589, UCN-01 or the combina-
tion of these drugs in a fixed ratio. Cell viability was assessed using
CT-Blue assay, and the effect was analyzed using median effect
analysis. As shown in Figures 6B and 6C, exposure of cells to the
combination of LBH589 and Chk1 inhibitors exerted a strong
synergistic effect. Using these same methods, a synergistic
interaction was also seen between LBH589 and a novel Chk1
inhibitor AZD7762 [28] in NSCLC cells that resulted in a CI
Figure 4. A, HDACi-mediated decrease in CHK1 precedes apoptosis. A549 cells were untreated or treated with LBH589 (40 nM) for various
time points. Cell lysates were prepared, and protein expression levels of cPARP, CHK1, Tyr15 phosphorylation of pCDC2 (pCDC2
Y15), Ser216
phosphorylation of CDC25C (pCDC25
S216), acetyl-H4, and cyclin B1 were determined. B, Quantitative Chk1 mRNA expression analysis. Total RNA was
prepared from A549 cells after 24 hours of treatment with 40 nM LBH589 or vehicle. mRNA expression levels were quantified using Real-time PCR
analysis. All results were normalized to GAPDH mRNA levels, and the mean and standard deviations values from four independent experiments are
shown. C, Ectopic expression of Chk1 reverses HDACi-induced apoptosis but not histone acetylation. A549 cells were transiently transfected with an
empty vector (control) or GFP- or FLAG-tagged (GFP-CHK1 or FLAG-CHK1) Chk1 expression plasmid. Forty-eight hours after transfection, cells were
cultured without (control, C) or with LBH589 (L) (40 nM) for an additional 24 hour before harvesting for Western blot analysis. Treatment-induced
changes in cPARP, acetyl-H4, phospho-CDC2
Y15, and ectopically expressed GFP-CHK1 or FLAG-CHK1 proteins were determined by Western blot
analysis. b-actin expression was used as loading control. Experiments were repeated 3 times, and a representative experiment is shown. The arrows
show the position of the GFP-CHK1 and FLAG-CHK1 proteins. D, in primary NSCLC patient samples, Chk1 protein downregulation correlates with
increased cPARP ex vivo. Tumor samples were collected with a 23-gauge needle from patient-derived tumors, and cells were treated in duplicate with
vehicle (control) or LBH589 (40 nM) for 18 hours. Following treatment, adherent and non-adherent cells were pooled, cell extracts were prepared,
and expression levels of cPARP, Chk1, and acetyl-H3 were analyzed by Western blot. b-actin expression was used as loading control. SCC: squamous
cell carcinoma; AC: adenocarcinoma.
doi:10.1371/journal.pone.0014335.g004
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shown).
The data presented above suggest that drugs inhibiting the
activity of proteins that negatively regulate the function of cdc2-
cyclin B complex may enhance the G2 checkpoint abrogation and
cytotoxic effects of HDACis in tumor cells.
Discussion
Previous studies have shown that HDACi-induced cell death is
associated with aberrant mitosis and disruption of the cell cycle
checkpoints [29–34]. However, the molecular mechanisms by
which HDACi treatment leads to mitotic cell death is not well
understood. Here, we demonstrated that HDACi treatment of
human NSCLC cells leads to downregulation of total Chk1
protein levels. We showed that this downregulation is biologically
relevant by demonstrating a concomitant decrease in the levels of
the inhibitory phosphorylation of key cell-cycle regulatory proteins
cdc25c and cdc2. The decreased levels of total Chk1 protein
preceded induction of apoptosis and histone acetylation, demon-
strating that Chk1 downregulation is an early event in HDACi
mode of action and that it plays a pivotal role in drug-mediated
cell death.
Chk1 expression has been shown to fluctuate during the cell
cycle [35]. However, since Chk1 is mainly expressed at the S to
M phase of the cell cycle at both the RNA and protein levels [35],
it is unlikely that HDACi-mediated inhibition of Chk1 is a
consequence of growth arrest in G2/M phase. RT-PCT
experiments demonstrated that transcriptional inhibition of
Chk1 plays an important role in HDACi-mediated regulation
of Chk1 protein. The mechanism by which HDACis regulate the
transcriptional expression of Chk1 is unknown and remains to be
elucidated.
Treatment of tumor cells with pan HDACis has been reported
to cause acetylation of Hsp90 through inhibition of HDAC6 and
depletion of several Hsp90 client proteins including AKT and c-
RAF [22,36,37]. Our results showed that under the conditions
where LBH589 induced Chk1 downregulation, no inhibition was
observed in the expression levels of AKT and c-RAF. Further-
more, selective HDAC inhibitors valproic acid, apicidin and MS-
275 with no known inhibitory effects on HDAC6 were able to
inhibit Chk1 expression. Taken together, these results suggest that
inhibition of Chk1 expression in HDACi-treated cells is likely not
mediated by inactivation of HSP90 protein, but is rather due to
repression of CHK1 expression.
One of the major challenges in the development of HDACis is
the definition of the clinically relevant endpoints to assess drug
efficacy in patient tumors at the early stage of treatment to predict
clinical outcome. In the present study, we showed that
downregulation of total Chk1 protein levels correlates much more
strongly with induction of cytotoxic effect rather than with histone
hyperacetylation in both cell lines and in primary NSCLC cells
obtained from patient tumors ex vivo. Together, these findings
suggest that downregulation of Chk1 and Tyr15 phosphorylation
Figure 5. Purvalanol A (Pur A) pretreatment diminishes the cytotoxic effect of LBH589 in A549 cells. Cells treated with LBH589 40 nM
with or without Pur A (10 mM) pretreatment were analyzed by flow cytometry for cell cycle distribution or by Western blot to determine drug-
mediated changes in cPARP. b-actin was used as a loading control.
doi:10.1371/journal.pone.0014335.g005
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dynamic markers of efficacy of HDACis.
Despite their promise as an emerging cancer therapy, in clinical
trials, the effectiveness of HDACis has been limited, and no clear
mechanism of resistance has been elucidated [1]. Our present
results provide a possible insight into the mechanism of HDACi
action and resistance. We showed that ectopic expression of Chk1
and prevention of mitotic entry by a cdc2 inhibitor purvalanol A
diminished LBH589-induced cell death. These findings suggest
that the level of Chk1 expression or activation status of enzymes
regulating the M-phase entry, such as cdc25 and cdc2-cyclin B
complex, may play an important role in determining sensitivity or
resistance of tumor cells to HDACis. The data presented here
suggest a model where mitotic entry is a required step for HDACi-
mediated cell death. Additionally, cellular mechanisms that block
Chk1 downregulation and/or bypass Chk1 and directly act on G2
checkpoint control to prevent cells from entering mitotic phase
would cause resistance to HDACis. For example, Chk1 has been
shown to be highly expressed in NSCLC tumors [38], which may
confer resistance to HDACi-induced mitotic entry and cell death.
Thus, in tumors with increased Chk1 activity, rational combina-
tions of HDACis with drugs that simultaneously inhibit Chk1 and
its downstream signaling pathways controlling G2/M cell cycle
checkpoint may augment the cytotoxic effects of HDACis.
HDACis have been shown to synergize with DNA damaging
agents [1]. However, the molecular mechanisms of this synergy
have not well been understood. Since Chk1 is crucial for the G2
checkpoint activation and survival after treatment with DNA
damaging agents, we speculate that inhibition of Chk1 might
provide a molecular explanation for the enhancement of tumor
sensitivity to chemotherapeutic agents by HDACis. Further studies
are required to elucidate the precise role of Chk1 in the synergistic
interaction of HDACis with the cytotoxic therapies to enhance
their therapeutic efficacy in cancer treatment.
Here, we provide evidence that HDAC and Chk1 inhibitors
show strong synergistic interaction in NSCLC cells, providing the
foundation for future clinical translation with HDACis and Chk1
inhibitors that are currently in clinical studies for anticancer
therapy. We expect that validation of Chk1 and its downstream
effectors involved in G2/M checkpoint control as clinically
relevant biomarkers of treatment efficacy could provide tools
applicable to the enrichment of clinical trials and, hopefully,
individualized tailoring of therapy of NSCLC.
Materials and Methods
Cell culture and experimental treatments
A549, H1299, H358, H441, H292, HCC827 (ATCC, Mana-
ssas, VA) and PC9 cells (provided by Dr. Matt Lazzara, University
of Pennsylvania, Philadelphia, PA) were grown in RPMI
supplemented with 5% fetal calf serum (FCS), 1% (v/v)
penicillin-streptomycin, and 1% (v/v) L-glutamine at 37uCi na
Figure 6. LBH589 and Chk1 inhibitor treatment shows a synergistic effect in NSCLC cells. A, A549 cells were treated with LBH589 40 nM
and/or a UCN-01 (250 nM) for 24 hours, cell extracts were prepared, and Western blot analysis was performed with PARP (t: total, c: cleaved).
Experiments were repeated at least 3 times, and a representative experiment is shown. B, A549 cells were treated with LBH589 and UCN-01 either
alone or in combination at a constant ratio (1:40) for 72 hours. Drug concentrations are indicated on the horizontal axis and plotted against cell
viability of control wells, which was arbitrarily set at 100% viability for each experiment. Error bars represent 6 SD of 4 replicate wells. C, combined
effects of LBH589 and Chk1 inhibitor UCN-01 were quantified with the Chou and Talalay combination index (CI) method (40). The CI used for drug
combination analyses was determined by the isobologram equation (see text). Ranking symbols (+/2) indicate average calculated Chou and Talalay
combination index (CI) range (+++, strong synergism).
doi:10.1371/journal.pone.0014335.g006
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01 (EMD Biosciences, San Diego, CA) and AZD7762 (Selleck
Chemical), HDACis scriptaid (BioMol International, Plymouth
Meeting, PA), LBH589 (Novartis, Basel, Switzerland), apicidin
(EMD Biosciences, San Diego, CA) and MS-275 (Selleck
Chemical) were dissolved in DMSO and added to the media at
the indicated concentrations. Stock solution of the HDACi
valproic acid (EMD Biosciences) was dissolved in water and
added to the media at the indicated concentrations. Control cells
were treated with vehicle alone.
Ex vivo assays of primary NSCLC samples
Tumor cells were collected by fine needle aspiration technique,
as previously described [39], from surgically resected Moffitt
Cancer Center patient tumors. The tissue studies were approved
by our Institutional Review Board at the University of South
Florida. Briefly, tumor cells were obtained with sterile 23-gauge
needles, and all samples were confirmed to be enriched for cancer
cells by microscopic assessment. Approximately 25,000 tumor cells
were treated in duplicate with vehicle (control) or LBH589
(40 nM) in a humidified 5% CO2 incubator at 37uC for 18 hours.
No fibroblast or endothelial cell growth was observed. Following
treatment, non-adherent and adherent cells (only a few, collected
by scraping) were pooled together and centrifuged at 5006g for 5
minutes at 4uC. After they were washed with PBS, cells were lysed
in 100 mL of ice-cold lysis buffer [50 mmol/L Tris-HCl, 0.25 mol/
L NaCl, 0.1% (v/v) Triton X-100, 1 mmol/L EDTA, 50 mmol/L
NaF, and 0.1 mmol/L Na3VO4 (pH 7.4)] containing protease and
phosphatase inhibitors (Roche Molecular Biochemicals, Indiana-
polis, IN) and analyzed by Western blot.
Antibodies
Mouse total Chk1, mouse total Chk2, rabbit cdc2 Y15P, rabbit
cdc25c S216P, rabbit acetylated histones H3 and H4 (acetyl-H3 or
acetyl-H4), rabbit total cdc2, rabbit total cdc25c, rabbit total
cdc25a, rabbit total histone H3, rabbit cPARP, rabbit total AKT,
rabbit H3 S10P, and rabbit total c-RAF antibodies were obtained
from Cell Signaling Technology (Watertown, MA). Rabbit cyclin
B1 antibody was obtained from AbCam (Cambridge, MA).
Western blot analysis
Both adherent and detached cells in tissue culture wells were
collected in 15-mL conical tubes and centrifuged at 4uC for 5
minutes at 1000 rpm in an Eppendorf 5810R centrifuge. The
supernatant was removed, and the cell pellet was rinsed with ice-
cold TBS, after which RIPA lysis buffer was added. Samples were
sonicated, vortexed on ice every 10 minutes for 30 minutes, and
then transferred to 1.5-mL microcentrifuge tubes and centrifuged
for 10 minutes at 13,000 rpm at 4uC in an Eppendorf 5417R
microcentrifuge. We used the Pierce BCA assay kit to determine
protein concentrations, following manufacturer’s protocol
(Thermo Fisher Scientific, Rockford, IL). Samples were heated
to 95uC for 10 minutes prior to resolving on an SDS-PAGE using
a 4% stacking/10% resolving gel and transferred to a poly-
vinylidene difluoride membrane using a semi-dry transfer device
(BioRad Industries, Hercules, CA). The membrane was blocked
for 1 hour at room temperature in Pierce Superblock (Thermo
Fisher Scientific) and probed for various antibodies. Enhanced
chemiluminescent detection was performed following manufac-
turer’s protocols (Thermo Fisher Scientific). Quantitation of
Western Blots was done using AlphaEase FC software (Cell
Biosciences, Inc., Santa Clara, CA).
Determination of Annexin V Positive Cells by Flow
Cytometry
A549 or PC9 NSCLC cells were seeded in 6-well plates at a
density of (4610
5) cells/well. Cells were treated the next day with
40 nM LBH589 and collected 24 hours later for analysis using the
BD Annexin V-FITC/7-AAD Flow Cytometry kit (BD Bioscience,
San Jose, CA, 559763) per manufacturer’s protocol. Cells were
trypsinized with 0.05% w/v trypsin (Invitrogen Corp, Carlsbad,
CA, 25300) and centrifuged for 5 minutes at 1000 rpm at 4uCi n
an Eppendorf Model 5417R centrifuge. Cell pellets were then
rinsed 1x with ice-cold 1x DPBS and centrifuged again for 5
minutes at 1000 rpm and 4uC. Cells were then re-suspended in 1x
Annexin V Binding Buffer at a concentration of 1610
6 cells/mL.
An aliquot of 100 uL of this cell suspension was then stained by
addition of 5 uL Annexin V-FITC solution and 10 uL 7-AAD
solution and allowed to incubate for 15 minutes on ice in the dark.
Positive control cells were prepared by heating an aliquot of cells
to 98uC for 2 minutes. Separate aliquots of cells were prepared for
Annexin V-FITC only controls and 7-AAD only controls. Aliquots
of healthy, untreated cells were added to these controls post-
heating to obtain a representative profile of healthy and unhealthy
populations for gating. After the 15 minute incubation was
completed, 400 uL of Annexin V Binding Buffer was added to
each sample and mixed. Samples were analyzed within 30 minutes
on a BD FACScan instrument with FLOWJO software to
determine the percentage of Annexin V positive cells.
Transfection experiments
The pGFP-CHK1 plasmid was purchased from Dana Farber/
Harvard Cancer Center DNA Resource Core. The pFLAG-
CHK1 plasmid was provided by Dr. Helen M. Piwnica-Worms,
Washington University, St. Louis, MO. All transfections were
carried out in 6-well culture plates maintained at 37uCi na5 %
CO2 incubator. Twenty-four hours before transfection, 5610
5
A549 cells were seeded in each well. Cells were transfected with
1 mg plasmid DNA using Lipofectamine with Plus Reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocols. Twenty-four hours post-transfection, cells were treated
with HDACi for 24 hours prior to collection for Western blot
analysis. Untransfected control cells were collected 48 hours post-
transfection.
Cell growth and viability assays
A549 cells were treated with LBH589 and UCN-01 alone or in
combination at a constant ratio for 72 hours. Cell viability was
measured by the CT-Blue assay (Promega). The combined effects
of LBH589 and UCN-O1 were quantified using a combination
index (CI) method developed by Chou and Talalay [40]. This
method involves plotting dose-effect curves for each agent and
their combination, using a median-effect equation: fa/fu = (D/
Dm)m, where D is dose of drug, Dm is dose required for a 50%
effect (equivalent to IC50), fa and fu are affected and unaffected
fractions, respectively (fa =1 - fu), and m is the exponent signifying
the sigmoidicity of the dose-effect curve. The computer software
Xlfit version 4.3.1 (ID Business Solutions) was used to calculate the
values of Dm and m. The CI used for the analysis of the drug
combinations was determined by the isobologram equation for
mutually nonexclusive drugs that have different modes of action:
CI =(D)1/(Dx)1+ (D)2/(Dx)2+ [(D)1(D)2]/[(Dx)1(Dx)2], where
(D)1 and (D)2 are relative concentrations of drugs 1 and 2 and x is
the percentage of inhibition. CI ,1, CI =1, and CI .1 indicate
synergism, additive effects, and antagonism, respectively.
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After they were rinsed with PBS, A549 or PC9 cells were
collected at various time points after HDACi treatment and fixed
in 70% ethanol while vortexing. Fixed cells were stored overnight
at 220uC. The following day, cells were washed twice in PBS and
treated with RNase A at 37uC for 30 minutes. Propidium iodide
was then added to the cells, and cells were allowed to incubate in
the dark for 1 hour at room temperature. Cells were then analyzed
by flow cytometry using a fluorescence-activated cell sorter (BD
Bioscience, San Jose, CA), Cell-Quest and FlowJo analysis
software.
Immunocytochemistry
A549 cells were grown to 50% confluence on sterile glass
coverslips in 6-well plates. Twenty-four hours after they were
seeded, cells were treated with 40 nM LBH589 for 24 hours. Cells
were then fixed in ice-cold 4% (w/v) p-formaldehyde in PBS for 15
minutes and permeabilized with 0.15% Triton X-100 for 30
minutes. Cells were then blocked with 5% bovine serum albumin
(Thermo Fisher Scientific) in PBS for 1 hour at room temperature
and probed with rabbit cPARP antibody (Cell Signaling
Technology) at a dilution of 1:50 overnight at 4uC. After they
were washed three times in PBS, cells were incubated for 1 hour at
room temperature with AlexaFluor 596 conjugated goat anti-
rabbit secondary antibody (Molecular Probes, Eugene, OR) at a
dilution of 1:200. Coverslips were then mounted on slides using
Vector Mount containing DAPI nuclear stain (Molecular Probes).
We viewed slides with a Zeiss-inverted microscope, analyzed with
Axiovert software.
Quantitative reverse transcription-PCR
RNA was isolated using the RNeasy kit (Qiagen 74104). First
strand cDNA was synthesized from 1 mg of RNA using Bio-Rad
iScript cDNA synthesis kit (Bio-Rad, 170-8891) in 20 ul reaction
volume. Real-time PCR was performed using Bio-Rad iQ SYBR
Green Supermix (Bio-Rad, 170-8882) on a MyiQ Single Color
Real-time PCR detection system. 1 ul of cDNA was used in each
25 ul PCR reaction. The following primers were used: CHK1
forward, 59-TGC TCA GAG ATT CTT CCA TC-39; CHK1
reverse, 59-AAC GCT CAC GAT TAT TAT ACC-39; GAPDH
forward, 59-GAG TCA ACG GAT TTG GTC GT-39; GAPDH
reverse, 59-TTGATTTTGGAGGGATCTCG-39. GAPDH was
served as internal control.
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